Brief: Oncbiomune awaits approval from regulatory committee to commence phase 2 trial of proscavax
31/08/2017 13:38
Aug 31 (Reuters) - Oncbiomune Pharmaceuticals Inc OBMP.PK
* Oncbiomune awaits approval from regulatory committee to
commence phase 2 trial of proscavax as front line prostate
cancer treatment
Source text for Eikon: ID:nMKWtCVhwa
Further company coverage: OBMP.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Theralink Technologies
See all newsBrief: IMAC Holdings - Theralink Will Merge With Newly-Formed Unit Of IMAC In A Stock-For-Stock Reverse Merger Transaction
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say (updated)
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say
Brief: Theralink Technologies Appoints Faith Zaslavsky As President, COO
Brief: Theralink Technologies Appoints Mattia Cremona As Director Of Its Biopharma Laboratory